Early access
Sign in
Not yet recruitingPhase 1/2

Imaging test with a radioactive tracer to find prostate cancer

Tests a radioactive PET scan tracer in men with prostate cancer.

Key facts

Who runs it
Radboud universitair medisch centrum Stichting
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Registry title
[89Zr]Zr-PSMA-N139 PET/CT imaging in primary and recurrent prostate cancer.
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
20 people, planned
Started
1 Oct 2026
Expected to end
1 Nov 2027
Type of study
Interventional
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer, either newly diagnosed or returned after earlier treatment. It tests PET/CT imaging with [89Zr]Zr-PSMA-N139.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma, newly diagnosed (primary) or recurrent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Imaging test with a radioactive tracer to find prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Record updated
9 November 2026